Impact of Excipients on Stability of Polymer Microparticles for Autoimmune Therapy.
Date
2021-02-11Journal
Frontiers in Bioengineering and BiotechnologyPublisher
Frontiers Media S.A.Type
Article
Metadata
Show full item recordAbstract
Therapies for autoimmune diseases such as multiple sclerosis and diabetes are not curative and cause significant challenges for patients. These include frequent, continued treatments required throughout the lifetime of the patient, as well as increased vulnerability to infection due to the non-specific action of therapies. Biomaterials have enabled progress in antigen-specific immunotherapies as carriers and delivery vehicles for immunomodulatory cargo. However, most of this work is in the preclinical stage, where small dosing requirements allow for on-demand preparation of immunotherapies. For clinical translation of these potential immunotherapies, manufacturing, preservation, storage, and stability are critical parameters that require greater attention. Here, we tested the stabilizing effects of excipients on the lyophilization of polymeric microparticles (MPs) designed for autoimmune therapy; these MPs are loaded with peptide self-antigen and a small molecule immunomodulator. We synthesized and lyophilized particles with three clinically relevant excipients: mannitol, trehalose, and sucrose. The biophysical properties of the formulations were assessed as a function of excipient formulation and stage of addition, then formulations were evaluated in primary immune cell culture. From a manufacturing perspective, excipients improved caking of lyophilized product, enabled more complete resuspension, increased product recovery, and led to smaller changes in MP size and size distribution over time. Cocultures of antigen-presenting cells and self-reactive T cells revealed that MPs lyophilized with excipients maintained tolerance-inducing function, even after significant storage times without refrigeration. These data demonstrate that excipients can be selected to drive favorable manufacturing properties without impacting the immunologic properties of the tolerogenic MPs. © Copyright © 2021 Gosselin, Noshin, Black and Jewell.Rights/Terms
Copyright © 2021 Gosselin, Noshin, Black and Jewell.Keyword
autoimmunityexcipient
formulation
immunotherapy
lyophilization
multiple sclerosis
nanotechnology
stability
Identifier to cite or link to this item
http://hdl.handle.net/10713/14863ae974a485f413a2113503eed53cd6c53
10.3389/fbioe.2020.609577
Scopus Count
Collections
Related articles
- Development of lyophilized gemini surfactant-based gene delivery systems: influence of lyophilization on the structure, activity and stability of the lipoplexes.
- Authors: Mohammed-Saeid W, Michel D, El-Aneed A, Verrall RE, Low NH, Badea I
- Issue date: 2012
- Excipients for the lyoprotection of MAPKAP kinase 2 inhibitory peptide nano-polyplexes.
- Authors: Mukalel AJ, Evans BC, Kilchrist KV, Dailing EA, Burdette B, Cheung-Flynn J, Brophy CM, Duvall CL
- Issue date: 2018 Jul 28
- A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody.
- Authors: Cleland JL, Lam X, Kendrick B, Yang J, Yang TH, Overcashier D, Brooks D, Hsu C, Carpenter JF
- Issue date: 2001 Mar
- Manufacturing and ambient stability of shelf freeze dried bacteriophage powder formulations.
- Authors: Zhang Y, Peng X, Zhang H, Watts AB, Ghosh D
- Issue date: 2018 May 5
- Effects of formulation and process variables on the aggregation of freeze-dried interleukin-6 (IL-6) after lyophilization and on storage.
- Authors: Lueckel B, Helk B, Bodmer D, Leuenberger H
- Issue date: 1998 Aug